Video

An important topic at the 2014 Summer AAD Meeting in Chicago, Illinois, was the nonsurgical treatment of skin cancers, including adjuvant therapy, topical creams, photodynamic therapy, and radiation for melanoma and nonmelanoma skin cancers. Dr. Anthony M. Rossi discusses the benefits of some of these nonsurgical treatment options for skin cancers and describes how he uses them in his practice. He also discusses how to determine which treatment option is best for each patient and emphasizes the importance of patient compliance and close follow-up.

An important topic at the 2014 Summer AAD Meeting in Chicago, Illinois, was the nonsurgical treatment of skin cancers, including adjuvant therapy, topical creams, photodynamic therapy, and radiation for melanoma and nonmelanoma skin cancers. Dr. Anthony M. Rossi discusses the benefits of some of these nonsurgical treatment options for skin cancers and describes how he uses them in his practice. He also discusses how to determine which treatment option is best for each patient and emphasizes the importance of patient compliance and close follow-up.

An important topic at the 2014 Summer AAD Meeting in Chicago, Illinois, was the nonsurgical treatment of skin cancers, including adjuvant therapy, topical creams, photodynamic therapy, and radiation for melanoma and nonmelanoma skin cancers. Dr. Anthony M. Rossi discusses the benefits of some of these nonsurgical treatment options for skin cancers and describes how he uses them in his practice. He also discusses how to determine which treatment option is best for each patient and emphasizes the importance of patient compliance and close follow-up.

PARIS – Thanks to microarray analysis of gene expression in patients with juvenile idiopathic arthritis, response to treatment at 12 months can be predicted after just 4 months of therapy, based on a longitudinal analysis of whole blood samples from children participating in the TREAT study.

The prediction of active versus inactive disease could be made even more strongly when stratifying patients based on the presence of rheumatoid factor (RF), which is an "exciting" finding, study investigator Dr. James Jarvis said in a video interview at the annual European Congress of Rheumatology. "We’ve known for a long time that children with rheumatoid factor–positive disease are just harder to treat."

The National Institutes of Health–funded TREAT (Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis) study compared treatment with methotrexate alone against methotrexate plus etanercept for children with newly diagnosed juvenile idiopathic arthritis. The current analysis found that treatment in RF-positive patients led to changes in fewer genes than in RF-negative patients, and also changed the expression of different genes than in those with RF-negative disease. Dr. Jarvis is chief of allergy/immunology and rheumatology in the pediatrics department at the University at Buffalo, The State University of New York.

[email protected]

PARIS – Thanks to microarray analysis of gene expression in patients with juvenile idiopathic arthritis, response to treatment at 12 months can be predicted after just 4 months of therapy, based on a longitudinal analysis of whole blood samples from children participating in the TREAT study.

The prediction of active versus inactive disease could be made even more strongly when stratifying patients based on the presence of rheumatoid factor (RF), which is an "exciting" finding, study investigator Dr. James Jarvis said in a video interview at the annual European Congress of Rheumatology. "We’ve known for a long time that children with rheumatoid factor–positive disease are just harder to treat."

The National Institutes of Health–funded TREAT (Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis) study compared treatment with methotrexate alone against methotrexate plus etanercept for children with newly diagnosed juvenile idiopathic arthritis. The current analysis found that treatment in RF-positive patients led to changes in fewer genes than in RF-negative patients, and also changed the expression of different genes than in those with RF-negative disease. Dr. Jarvis is chief of allergy/immunology and rheumatology in the pediatrics department at the University at Buffalo, The State University of New York.

[email protected]

PARIS – Thanks to microarray analysis of gene expression in patients with juvenile idiopathic arthritis, response to treatment at 12 months can be predicted after just 4 months of therapy, based on a longitudinal analysis of whole blood samples from children participating in the TREAT study.

The prediction of active versus inactive disease could be made even more strongly when stratifying patients based on the presence of rheumatoid factor (RF), which is an "exciting" finding, study investigator Dr. James Jarvis said in a video interview at the annual European Congress of Rheumatology. "We’ve known for a long time that children with rheumatoid factor–positive disease are just harder to treat."

The National Institutes of Health–funded TREAT (Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis) study compared treatment with methotrexate alone against methotrexate plus etanercept for children with newly diagnosed juvenile idiopathic arthritis. The current analysis found that treatment in RF-positive patients led to changes in fewer genes than in RF-negative patients, and also changed the expression of different genes than in those with RF-negative disease. Dr. Jarvis is chief of allergy/immunology and rheumatology in the pediatrics department at the University at Buffalo, The State University of New York.

[email protected]

Vidyard Video

Read Dr. Kho's Surgical Technique article, "Transforming vaginal hysterectomy: 7 solutions to the most daunting challenges" (August 2014)

Vidyard Video

Read Dr. Kho's Surgical Technique article, "Transforming vaginal hysterectomy: 7 solutions to the most daunting challenges" (August 2014)

Vidyard Video

Read Dr. Kho's Surgical Technique article, "Transforming vaginal hysterectomy: 7 solutions to the most daunting challenges" (August 2014)

CHICAGO – The data are still being developed, but evidence of a direct link between stress and inflammatory skin conditions continues to mount.

The research is especially compelling for psoriasis; experimental data suggest that stress triggers the nerves to release elevated levels of neuropeptides and neurotransmitters, which in turn affect the nervous system.

Dr. Richard Granstein, chairman of the dermatology department at Weill Cornell Medical College in New York, gave an exclusive interview to Frontline Medical News in which he described studies of how calming the nerves clearly interrupts psoriatic and other inflammatory skin conditions. Dr. Granstein discussed the implications of this new, and still controversial, line of research, and what this means for clinicians: Should they prescribe stress management programs to their patients with these skin conditions?

Dr. Granstein disclosed he has financial relationships with Velius and Clinique.

[email protected]

On Twitter @whitneymcknight

CHICAGO – The data are still being developed, but evidence of a direct link between stress and inflammatory skin conditions continues to mount.

The research is especially compelling for psoriasis; experimental data suggest that stress triggers the nerves to release elevated levels of neuropeptides and neurotransmitters, which in turn affect the nervous system.

Dr. Richard Granstein, chairman of the dermatology department at Weill Cornell Medical College in New York, gave an exclusive interview to Frontline Medical News in which he described studies of how calming the nerves clearly interrupts psoriatic and other inflammatory skin conditions. Dr. Granstein discussed the implications of this new, and still controversial, line of research, and what this means for clinicians: Should they prescribe stress management programs to their patients with these skin conditions?

Dr. Granstein disclosed he has financial relationships with Velius and Clinique.

[email protected]

On Twitter @whitneymcknight

CHICAGO – The data are still being developed, but evidence of a direct link between stress and inflammatory skin conditions continues to mount.

The research is especially compelling for psoriasis; experimental data suggest that stress triggers the nerves to release elevated levels of neuropeptides and neurotransmitters, which in turn affect the nervous system.

Dr. Richard Granstein, chairman of the dermatology department at Weill Cornell Medical College in New York, gave an exclusive interview to Frontline Medical News in which he described studies of how calming the nerves clearly interrupts psoriatic and other inflammatory skin conditions. Dr. Granstein discussed the implications of this new, and still controversial, line of research, and what this means for clinicians: Should they prescribe stress management programs to their patients with these skin conditions?

Dr. Granstein disclosed he has financial relationships with Velius and Clinique.

[email protected]

On Twitter @whitneymcknight